Insider Selling: Oscar Health, Inc. (NYSE:OSCR) EVP Sells 19,157 Shares of Stock

Oscar Health, Inc. (NYSE:OSCR) EVP Ranmali Bopitiya sold 19,157 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $18.08, for a total value of $346,358.56. Following the sale, the executive vice president now owns 241,488 shares in the company, valued at approximately $4,366,103.04. The trade was a 7.35 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Oscar Health Trading Down 3.3 %

Shares of Oscar Health stock opened at $16.40 on Friday. The firm has a market cap of $4.06 billion, a PE ratio of -273.33 and a beta of 1.63. The stock has a fifty day moving average price of $17.08 and a 200-day moving average price of $17.93. The company has a debt-to-equity ratio of 0.26, a current ratio of 0.73 and a quick ratio of 0.73. Oscar Health, Inc. has a 1 year low of $7.50 and a 1 year high of $23.79.

Oscar Health (NYSE:OSCR) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.02). The firm had revenue of $2.42 billion during the quarter, compared to the consensus estimate of $2.33 billion. Oscar Health had a net margin of 0.35% and a return on equity of 2.79%. The company’s revenue was up 68.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.29) earnings per share. Equities research analysts anticipate that Oscar Health, Inc. will post -0.01 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have issued reports on OSCR shares. Piper Sandler reissued an “overweight” rating and issued a $28.00 price target on shares of Oscar Health in a research note on Tuesday, September 10th. Bank of America downgraded shares of Oscar Health from a “neutral” rating to an “underperform” rating and dropped their target price for the company from $21.00 to $13.50 in a research report on Wednesday, November 6th. Finally, UBS Group started coverage on Oscar Health in a report on Monday, October 7th. They issued a “neutral” rating and a $23.00 price target on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $22.93.

Hedge Funds Weigh In On Oscar Health

Large investors have recently made changes to their positions in the stock. Simplicity Wealth LLC bought a new stake in shares of Oscar Health during the second quarter valued at about $179,000. SG Americas Securities LLC increased its holdings in Oscar Health by 900.6% during the 2nd quarter. SG Americas Securities LLC now owns 190,039 shares of the company’s stock worth $3,006,000 after acquiring an additional 171,047 shares during the period. Assenagon Asset Management S.A. lifted its stake in Oscar Health by 32.9% in the 2nd quarter. Assenagon Asset Management S.A. now owns 2,046,046 shares of the company’s stock worth $32,368,000 after purchasing an additional 507,009 shares in the last quarter. Raymond James & Associates bought a new position in Oscar Health in the 2nd quarter valued at $3,168,000. Finally, Hennessy Advisors Inc. purchased a new position in shares of Oscar Health during the 2nd quarter valued at $9,047,000. 75.70% of the stock is owned by institutional investors.

About Oscar Health

Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.